Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
SDĚLENÍ
Xxxxxxxxxxxx xxxxxxxxxxxx věcí,
xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Sb. x. x., x. 46/2008 Sb. x. x. x x. 47/2012 Xx. x. x. x Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Seznamu xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx.1)
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Parlament Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx I xxxxxxxxx x platnost x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2012 x tímto xxxx xxxxxxxxx x xxxxxxxx x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx platit znění Xxxxxxx X Xxxxxxxxxxx xxxxxx proti dopingu xx sportu xxxxxx xx 1. xxxxx 2011 x xxxxxxxxx xxx č. 47/2012 Sb. m. s.
Anglické xxxxx Přílohy I x xxxx překlad xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Mezinárodní xxxxxx proti dopingu xx xxxxxx xxxxxxx xxx 19. října 2005 x Xxxxxx xxxx vyhlášena xxx č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Seznam xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX LÁTEK X XXXXX XXXXXXX XXX XXX 2012
SVĚTOVÝ XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2012
Podle xxxxxx 4.2.2 Xxxxxxxxx antidopingového xxxxxx xxxxxxx Zakázané xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, X4.4, S4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 x M3.
XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX) |
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx látka, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x není aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
S1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx jsou zakázány.
1. ANDROGENNÍ ANABOLICKÉ XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, zahrnující:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (estr-4-en-3β,17β-diol); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; mestanolon; mesterolon; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; norethandrolon; norklostebol; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-5α-androstano [3,2-x]xxxxxxx); quinbolon; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, xxxxx xxxx podány xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x jejich xxxxxxxxxx x xxxxxxx, ale xx x omezením xxxxx na xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-androstendion (androst-5-en-3,17-dion) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-xxxxxxxxx-3β,17α-xxxx | xxx-xxxxxxxxxxxxxxxxxx |
5α-androstan-3β,17β-diol | xxxxxxxxxxxxxx |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
androst-4-en-3α,17β-diol | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-hydroxy-DHEA |
androst-5-en-3α,17β-dioI | 7-xxxx-XXXX |
androst-5-en-3β,17α-diol | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, kterou xxxx xxxx xxxxxxxxxx xxxxxxxxx. |
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx a xxxxxx uvolňující faktory xxxx xxxxxxxx:
1. Xxxxx stimulující xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), stabilizátory xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Xxxxxxxx/);
2. Choriogonadotropin (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxx;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx faktor-1 (IGF-1), xxxxxxxxxx xxxxxxx faktory (XXX), xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) a xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), stejně xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx syntézu xxxx degradaci xxxxxxxx xxxxx, xxxxx a xxxxxx, xxxxxx xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx xxxxxxxxx xxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.
X3. XXXX2- XXXXXXXX
Všichni xxxx-2 xxxxxxxx (xxxxxx xxxx xxxxxxxxxx optických xxxxxxx) jsou xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx pokud xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx výrobce.
Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x moči x xxxxxxxxxxx xxxxx xxx 30 xx/xx nebude xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx abnormální výsledek xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx xxxx xxxxxxx xxxxxxx.
S4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, zahrnující:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo),exemestan, formestan, xxxxxxxx, testolacton, xxx xx x omezením xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Raloxifen, tamoxifen, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:
Xxxxxxxxxx, fulvestrant, xxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx pouze xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Receptor xxxxx xxxxxxxxxx peroxizomovými xxxxxxxxxxxxx /Peroxisome Proliferator Xxxxxxxxx Xxxxxxxx δ (PPARδ) xxxxxxxx/ (xxxx. GW 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. DIURETIKA X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. glycerol, nitrožilní xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx x podobnými xxxxxxxxxxxx účinky. Xxxxxxx xxxxxxxx xxxxxxxxxxxx pro xxxxx xxxxxxxx xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx a xxxxxxxxx xxxxxx dorzolamidu x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) jakéhokoliv xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, katin, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx spojení s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx je xxxxxxxxxx udělení xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx udělena xx xxxxxxxxxx nebo xxxxx maskovací xxxxx.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx je následující:
1. Xxxxxx doping, xxxxxx použití xxxxxxxxx, xxxxxxxxx xxxx heterologní xxxx nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx dodávky xxxxxxx, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx xxxxx xx xx. Xxxxxxxx xxxxxxx xxxxxxxx xxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Podvádění, xxxx xxxxx o xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. To xxxxxxxx záměnu x/xxxx xxxxxx (xxxx. xxxxxxxxxx) xxxx, xxx xx x omezením pouze xx ně.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx jsou xxxxxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx nemocničních zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
3. Postupný xxxxx, manipulace a xxxxxxxxx jakéhokoliv množství xxxx xxxx xx xxxxxxxxx xxxxxxx je xxxxxxxx.
X3. GENOVÝ XXXXXX
Z xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx sekvencí;
2. Použití xxxxxxxxxx xxxx geneticky modifikovaných xxxxx;
XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX |
Xxxxx xxxxxxxxx XX xx X5 x X1 xx M3 xxxxxxxxx xxxx jsou Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Všechna xxxxxxxxxxx (xxxxxx obou jejich xxxxxxxxxx xxxxxxxxx isomerů) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx jejich xxxxxxxx xxxxxxx a xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx programu xxx xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, amifenazol, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, fenmetrazin, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), furfenorex, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metamfetamin (x-), xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.
Xxxxxxxxxxxx, které není xxxxxxxx xxxxxxx x xxxxx odstavci, xx Xxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxxx xxxxxxxxxxx (příklady):
Xxxxxxxxx**, xxxxx***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, meklofenoxát, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, parahydroxyamfetamin, xxxxxxx, xxxxxxxxxxx, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, strychnin, xxxxxxxxxxxxx a xxxxx xxxxx s podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx, synefrin) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx podání xxxxxxxxxx (xxxx. nosní, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx s xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx pouze xxx koncentraci xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x xxxxxxxxxxxxx jsou xxxxxxxx při koncentraci xxxxx než 10 xxxxxxxxxx x 1 xx moči.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx koncentrace x xxxx xx xxxxx než 150 xxxxxxxxxx xx mililitr
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x jeho xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (např. hašiš, xxxxxx a marihuana) xxxx xxxxxxxxxx xxxxx9xxxxxxxxxxxxxxxxxxx (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, XXX073/ x XX-210) xxxx xxxxxxxx.
X9. GLUKOKORTIKOSTEROIDY
Všechny xxxxxxxxxxxxxxxxxxxx podávané orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx aplikací jsou xxxxxxxx.
XXXXX XXXXXXXX X URČITÝCH XXXXXXXX |
P1. XXXXXXX
Alkohol (xxxxxx) xx zakázaný xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx pro porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je 0.10 x/x.
∙ Automobilový xxxxx (FIA)
∙ Xxxxxx (WKF)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Motocyklový xxxxx (FIM)
∙ Xxxxx motorismus (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Automobilový xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxxx (FMB)
∙ Golf (IGF)
∙ Xxxxxxx a xxxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Lyžování (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx X-xxxxx x "big air"
∙ Petanque a xxxxxxx xxxxxx (XXXX)
∙ Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, betaxolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
Informace
Xxxxxx xxxxxxx x. 97/2012 Xx. m. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Sb. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 98/2013 Sb. m. s. x xxxxxxxxx od 20.12.2013.
Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx právních předpisů x odkazech není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.